Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Zhu (South San Francisco, United States of America), R. Owen (South San Francisco, United States of America), T. Staton (South San Francisco, United States of America), K. Peng (South San Francisco, United States of America), C. Huang (South San Francisco, United States of America), M. Bremer (South San Francisco, United States of America), N. Meshgin (South San Francisco, United States of America), P. Banerjee (South San Francisco, United States of America), R. Bauer (South San Francisco, United States of America), F. Cai (South San Francisco, United States of America). Characterization of omalizumab partitioning in the nasal mucosa of patients. 1657

Member's Comments

No comment yet.

Related content which might interest you: Effect of mepolizumab on chronic rhinosinusitis symptoms and nasal hypersensitivity in patients with or without nasal polyps Source: Virtual Congress 2020 – Asthma management: role of biomarkers and comorbidities Year: 2020 Nasal mucosa biopsy in patients with severe bronchial asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Comparative effects of Mometason furoate and Zafirlukast in treatment of nasal polyps in asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 45s Year: 2002 Increased nasal mucosal swelling in subjects with asthma Source: Eur Respir J 2001; 18: Suppl. 33, 427s Year: 2001 Effect of oral and inhalation corticosteroids on osseous tissue condition for patients with bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 51s Year: 2002 Impact of mepolizumab in severe asthma with nasal polyps Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Efficacy of symbicort administration in patients with bronchial asthma Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 The ultrastructure of nasal mucosa in asthmatic children with and without allergic rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 398s Year: 2005 Eotaxins expression in nasal mucosa in patients with asthma and seasonal rhinitis Source: Annual Congress 2010 - Cell biology and immunology of lung disease Year: 2010 A combined bronchial, oral, and nasal challenge for aspirin-induced asthma Source: Eur Respir J 2004; 24: Suppl. 48, 444s Year: 2004 Mycobiota of the pharynx in patients with persistent bronchial asthma who constantly applying the inhaled corticosteroids Source: Annual Congress 2012 - Asthma: assessment and treatment Year: 2012 Mechanisms responsible for glucocorticoid insensitivity in nasal mucosa and nasal polyps Source: Annual Congress 2010 - COPD and asthma: models and human studies Year: 2010 A transcriptomic comparison between nasal and bronchial airway epithelia from children. Source: International Congress 2017 – Asthma genetics and genomics in patients and populations Year: 2017 Effects of a 12-month course with omalizumab on nasal polyps and basement membrane in severe atopic asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Monitoring of inflammatory changes in patients with bronchial asthma before and after oral corticosteroid treatment Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 Impact of biologic therapy in severe asthma with nasal polyps Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Expression of eotaxins in nasal mucosa of allergic patients after intranasal provocation- preliminary study Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation Year: 2013 Metabolic differences in bronchial epithelium from asthma patients and impact of bronchial thermoplasty Source: Virtual Congress 2020 – Metabolic alterations and ageing in lung disease Year: 2020